{"id":479399,"date":"2021-04-21T07:33:24","date_gmt":"2021-04-21T11:33:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/"},"modified":"2021-04-21T07:33:24","modified_gmt":"2021-04-21T11:33:24","slug":"cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/","title":{"rendered":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley\u2019s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.\u00a0\u00a0 Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.<\/p>\n

The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar<\/a>.\u00a0\u00a0 An archived replay of the event will be available on the site for approximately 90 days following the presentation.<\/p>\n

\n About\u00a0Cyclerion Therapeutics\u00a0<\/strong>
\n
Cyclerion Therapeutics\u00a0is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion\u2019s lead molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer’s Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).<\/p>\n

For more information about Cyclerion, please visit\u00a0https:\/\/www.cyclerion.com\/<\/a>\u00a0and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com\/company\/cyclerion<\/a>).<\/p>\n

\n Investors<\/strong>
\n
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com<\/a><\/p>\n

\n Media<\/strong>
\n
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley\u2019s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.\u00a0\u00a0 Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley. The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar.\u00a0\u00a0 An archived replay of the event will be available on the site for approximately 90 days following the presentation. About\u00a0Cyclerion Therapeutics\u00a0 Cyclerion Therapeutics\u00a0is a clinical-stage … <\/p>\n

Continue reading “Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479399","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley\u2019s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.\u00a0\u00a0 Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley. The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar.\u00a0\u00a0 An archived replay of the event will be available on the site for approximately 90 days following the presentation. About\u00a0Cyclerion Therapeutics\u00a0 Cyclerion Therapeutics\u00a0is a clinical-stage … Continue reading "Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T11:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference\",\"datePublished\":\"2021-04-21T11:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/\",\"name\":\"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=\",\"datePublished\":\"2021-04-21T11:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley\u2019s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.\u00a0\u00a0 Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley. The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar.\u00a0\u00a0 An archived replay of the event will be available on the site for approximately 90 days following the presentation. About\u00a0Cyclerion Therapeutics\u00a0 Cyclerion Therapeutics\u00a0is a clinical-stage … Continue reading \"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T11:33:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference","datePublished":"2021-04-21T11:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/","name":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=","datePublished":"2021-04-21T11:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc1MSM0MTMxMzUyIzIxMjUwMjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-the-b-riley-neuroscience-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479399"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479399\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}